Actinogen Medical
Jack Taylor is a seasoned professional in the field of clinical science and drug development, currently serving as a Senior Clinical Scientist at Actinogen Medical since February 2020, following roles as Clinical Scientist and Drug Development Officer. Prior experience includes working as a Regulatory Affairs Officer at The SPD Company Pty Ltd from November 2016 to May 2020 and as a Doctoral Candidate at the University of Technology Sydney, where significant research was conducted on microvesicle biogenic pathways in cancer cells. Jack's academic credentials include a Graduate Diploma in Clinical Epidemiology from the University of Sydney, a PhD in Cancer Cell Biology, a Master's in Pharmacy, and a Bachelor's in Neuroscience, all contributing to a strong foundation in healthcare and scientific research.
Actinogen Medical
1 followers
FOCUSED ON DEVELOPING AN INNOVATIVE TREATMENT FOR COGNITIVE IMPAIRMENT due to raised cortisol ASSOCIATED WITH NEUROLOGICAL DISEASES Ethics Committee approval for XanaMIA StudyActinogen has received approval from the Bellberry Human Research Ethics Comm...